News

Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. Merck

This transaction follows PDL’s earlier announced decision to actively pursue the sale of its key assets and is expected to close in the first quarter of 2008. Following

The company said that the new indication allows Thyrogen to be used in conjunction with radioiodine for the most common approach to treating thyroid cancer. This includes surgical

Atripla has been approved in the European Union for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels < 50copies/ml

At the special meeting of securityholders, the transaction was approved by over 99% of the votes cast by shareholders and by over 99% of the votes cast by

NOV-002 is in pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment and fast track. Lee’s Pharmaceutical, which is 30% owned by Sigma-Tau

In 2006, Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by the Medical House’s GH1. The Medical House has never been able to supply

In the randomized, double-blind, placebo controlled Phase II trial, 1mg dose of DDP225 administered once daily for eight weeks achieved a 71% response rate compared to a 25%

The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo.